Australia
Recce Pharmaceuticals Ltd announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant Research Hub in Sydney, Australia to combat antimicrobial resistance.
Recce Pharmaceuticals Ltd announced advances in scaled manufacture and drug quality following positive Food and Drug Administration feedback to its Chemistry, Manufacturing, and Controls data pack.
Researchers from The Westmead Institute for Medical Research have discovered how fatty liver disease develops in lean people, aiding the development of potential treatments for these patients.
St Vincent’s Institute of Medical Research in Melbourne, Australia, announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with focus on Alzheimer’s disease treatment.
Australia’s leading gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Race Oncology Limited announced the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett.
Osteoporosis is a disease where the bones become more porous and fragile, which dramatically increases the risk of bone fractures. It affects about 200 million people worldwide, is a progressive disease, and there are often are no symptoms until a fracture.
The research team found that some pancreatic tumors create a molecule that helps enable the spread of the cancer cells.
Recce Pharmaceuticals Limited announced the European Patent Office has granted its patent applications for wholly owned RECCE® antibiotics, including lead compound RECCE® 327 furthering marketing/manufacturing monopolies and expanding clinical indications.
PRESS RELEASES